김성훈 (연세대학교 융합과학기술원 & 의과대학, 세브란스병원)님 | 한빛사연구자 > 한빛사

연세대학교 융합과학기술원 & 의과대학, 세브란스병원

최종업데이트 2024.07.29.

Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1
- Mol. Ther., Available online 25 July 2024 | https://doi.org/10.1016/j.ymthe.2024.07.014
- 2024-07
- 의약학
- 한빛사논문
Disease association and therapeutic routes of aminoacyl-tRNA synthetases
- Trends Mol. Med , Nov 08 2023, S1471-4914(23)00241-1 | https://doi.org/10.1016/j.molmed.2023.10.006
- 2023-11
- 의약학
- 한빛사논문
Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl-tRNA synthetase 1
- EMBO Mol. Med., 22 May 2023 | https://doi.org/10.15252/emmm.202216940
- 2023-05
- 의약학
- 한빛사논문
AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis
- Nat. Commun., Published 11 May 2022 | https://doi.org/10.1038/s41467-022-30149-2
- 2022-05
- 의약학
- 한빛사논문
Extracellular vesicles derived from macrophages display glycyl‐tRNA synthetase 1 and exhibit anti‐cancer activity
- J. Extracell. Vesicles, Volume10, Issue1 November 2020 e12029 | https://doi.org/10.1002/jev2.12029
- 2020-11
- 의약학
- 한빛사논문

연구자 ID

저자논문